Verify directly with the insurer by brand name
So right now our main recommendation the body site plan plus the gluten free diet
Due to the current heterogeneity of clinical data, future research should focus on adequately powered, well-controlled randomised controlled trials (RCTs) that: incorporate redox biomarker panels and standardised outcomes (pain, FIQR, function, mood/sleep)
[DOI] [PubMed] [Google Scholar] Gonzlez-Gordo S, Rodrguez-Ruiz M, Lpez-Jaramillo J, Muoz-Vargas MA, Palma JM, Corpas FJ
The largest trial of ERAs, SONAR, including 2648 participants with type 2 diabetes and proteinuric CKD, demonstrated that atrasentan on top of RAS inhibition significantly lowered the risk of a doubling of serum creatinine or ESKD compared with placebo by 35% [75]